Only foreign markets are able to “digest” high valuation of China's biotech assets in primary market. RDC/RLT will become the next hot area for investment. Yiling’s performance would rebound in 24H2.
What is covered in the Full Insight:
Overvaluation in Primary Market
RDC as Potential Hot Spot
Shijiazhuang Yiling Pharmaceutical's Performance
Industry Viewpoints
Market Review
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.